Latest Interviews
Showing 1–2 of 2 transcripts.
Clear all filters- All-In Podcast37 min
Juan Carlos Izpisua Belmonte, Altos Labs | All-In Summit 2024
Juan Carlos Izpisua Belmonte, Chamath, Friedberg, Juan Carlos Espucía Belmonte, Juan Carlos Belmonde
Altos Labs, backed by a $3 billion seed investment, is advancing a partial reprogramming strategy that utilizes controlled pulses of Yamanaka factors to reverse aging by restoring closed chromatin conformation without altering the DNA sequence. Early experimental results demonstrate that this approach successfully extends lifespan and reverses specific age-related pathologies in mice and non-human primates, while ex vivo organ treatments show promise for improving transplant viability. With initial clinical applications targeted at acute conditions like liver failure, the company aims to transition from viral vectors to safer, scalable delivery methods to broadly enhance cellular resilience against age-related decline.
- All-In Podcast45 min
All-In Summit: Nuclear fusion and the potential for energy abundance
Robert Mumgaard, David Kirtley, Bob Momgard, Chamath, Calacanis, Friedberg
Leading fusion startups Commonwealth Fusion Systems and Helion Energy are racing to validate their distinct technologies, with targets to deliver net energy gain by 2026 and commercial power by 2028 respectively. These ventures leverage over $6 billion in private capital and advanced engineering to aim for electricity costs under one cent per kilowatt-hour, addressing the projected fivefold increase in global energy demand. Industry consensus indicates that no single architecture will dominate the coming energy transition, necessitating a portfolio of competing solutions to provide the thousands of gigawatts required for decarbonization and electrification.